Pointe-Claire, Canada Clinical Trials

A listing of Pointe-Claire, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 253 clinical trials
Featured trial
Sickle Cell Disease Study: Own Your Health, Share Your Story with PicnicHealth

Get all of your medical records in one secure account and contribute to important real-world Sickle Cell research with PicnicHealth. If you have Sickle Cell, you get $50 for signing up and a free lifetime access to your medical records.   Visit this link to learn more and sign up. …

Online studies
PicnicHealth
(online study) Contact site
  • 11 views
  • 04 Aug, 2022
  • 1 location
  • Online study
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

McGill University Health Center Research Institute /ID# 222614
 (9.7 away) Contact site
  • 833 views
  • 23 Jul, 2022
  • +225 other locations
Featured trial
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination …

MCGILL UNIVERSITY HEALTH CENTRE/GLEN SITE/CEDARS CANCER CENTRE
 (9.7 away) Contact site
  • 0 views
  • 22 Jul, 2022
  • +24 other locations
Featured trial
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.

rituximab
follicular lymphoma
marginal zone lymphoma
lenalidomide
McGill University Jewish General Hospital
 (8.4 away) Contact site
  • 5 views
  • 22 Jul, 2022
  • +177 other locations
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.   This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …

epoetin alfa
Sir Mortimer B Davis Jewish General Hospital
 (8.4 away)
  • 23119 views
  • 01 Jul, 2022
  • +9 other locations
Objective, Passive Assessment of LRRK2 Carriers (OPAL)

This study is currently only open to active participants in the University of Rochester’s VALOR-PD study. The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home. We will do so by using a wireless …

Online studies
movement disorder
University of Rochester
(online study) Contact site
  • 8 views
  • 12 May, 2022
  • 1 location
  • Online study
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.

McGill University Health Centre
 (9.7 away) Contact site
  • 56 views
  • 06 Apr, 2022
  • +15 other locations
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection (TAPER-V)

The first line therapy for an initial episode of CDI (Clostridium difficile infection) is 10-14 days of oral vancomycin which is now recommended over metronidazole in the 2018 guidelines from the Association of Medical Microbiologists and Infectious Diseases of Canada (AMMI). Although response rates for the treatment of a first …

Jewish General Hospital
 (8.4 away) Contact site
  • 0 views
  • 19 Apr, 2022
  • +2 other locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will be nine cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, …

testosterone
bone lesions
olaparib
solid tumour
receptor activator of nuclear factor kappa-b ligand
Merck Canada
 (2.7 away) Contact site
  • 3 views
  • 06 Jun, 2022
  • +30 other locations
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.

CHU Sainte-Justine
 (8.6 away) Contact site
  • 0 views
  • 30 May, 2022
  • +70 other locations